United Therapeutics Corp., of Silver Spring, Md., completed enrollment in the FREEDOM-C(2) registration trial of its sustained-release oral formulation of treprostinil diethanolamine (UT-15C). The 16-week, international, double-blind, randomized, placebo-controlled trial enrolled 313 subjects with pulmonary arterial hypertension.